(Q24243994)

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Myocarditis and idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Viral persistence in the myocardium is associated with progressive cardiac dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Herbal medicines for viral myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Do certain countries produce only positive results? A systematic review of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021

Immunopathogenesis and treatment of myocarditis: the United States Myocarditis Treatment Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021

The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021

Implications of the Myocarditis Treatment Trial for clinical practice.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021

Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021

The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: an overview

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004471.PUB2

7 January 2021